Many Older Sequencer Are Not Upgraded: Are they Not Used?

Recently Illumina reported a drop in preliminary Q3 revenues. They expect 1% less revenue compared to previous Q3, while Wall Street expected 17% growth (genomeweb). Illumina explains this with uncertainty in funding and higher throughput of the V3 sequencing Kit. They also report that the upgrade rate from Genome Analyzer to HiSeq 2000 was lower as expected and that the use of Genome Analyzer reagents dropped significantly.
In an earlier post I have already speculated that many sequencer are only used at a low percentage of their capacity. This might explain the low upgrade rate of older sequencer and the drop in use of reagents. They are simply not in use.
I have currently no information about the upgrade rate of Roche GS FLX/454 sequencer for use of the new FLX+ chemistry.
Did you upgrade your sequencer already?

Georg Gradl (Germany)

About Georg Gradl (Germany)

From the beginning, Georg is focusing on next generation technologies.

3 Responses to “Many Older Sequencer Are Not Upgraded: Are they Not Used?”

  1. Hello Georg
    Low usage might not be the only reason in the Illumina case. The upgrades on Illumina machines are also VERY expensive, so a lot of customers just dont do it.
    In the case of the genome analyser->Hiseq200 upgrade, I can imagine the price given by Illumina for the “old” GA must be really low.

    • Georg Gradl (Germany)

      Hello Ezequiel,
      Upgrading after a short time is certainly a big loss. On the other hand the sales of consumables for the GA is low according to Illumina. So the conclusion should be: They are not in use.

      • The throughput improvements announced on the SOLiD platform appear set to make it competitive with Illumina by year-end is it right to say Illumina’s dominance in that area is a given? Also, how much of a consideration are the much better accuracy for roughly similar throughput, and iprmovements in sample prep on SOLiD?